Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.bellushealth.com
Number of Employees: 74
Year Founded: 1993


Business Description
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.0
Market Capitalization
2,535.0
TEV/Total Revenue
NM
EBITDA
(122.3)
Total Enterprise Value
2,113.1
TEV/EBITDA
NM
EBIT
(122.8)
Cash & ST Invst.
425.4
P/Diluted EPS Before Extra
NM
Net Income
(118.0)
Total Debt
1.6
Price/Tang BV
5.8x
Total Assets
515.9
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of Mar-31-2023 TEV and Market Cap are calculated using a close price as of Jun-29-2023

Key Professionals
Name
Title
Bellini, Roberto Francesco
President, CEO & Director
Orfanos, Andreas 
Chief Operating Officer
Garceau, Denis 
Chief Scientific Officer
Matthews, Daniel 
Director of Investor Relations & Communications
Bonuccelli, Catherine M.
Chief Medical Officer
Matzouranis, Tony 
Chief Business Officer
Roy, Sebastien 
Corporate Secretary

Key Board Members
Name
Title
Bellini, Francesco 
Chairman of the Board
Bellini, Roberto Francesco
President, CEO & Director
Berger, Franklin M.
Independent Director
Larochelle, Pierre 
Independent Lead Director
Rus, Joseph 
Independent Director
Desjardins, Clarissa 
Independent Director
Mezzanotte, William 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
275 Armand-Frappier Boulevard | Laval, QC | H7V 4A7 | Canada
Phone: 450 680 4500   Fax: 450 680 4501

Parent Company
GSK plc (LSE:GSK)

Prior Investors
Amzak Capital Management, Atlas Venture L.P., BDC Capital Inc., BDC Health Venture Fund, BioCapital, BioCapital Biotechnology and Healthcare Fund, Canadian Medical Discoveries Fund Inc., Capital Ventures International, L.P., CDP Capital-Technology Ventures, Coller Capital Ltd., Cowen Inc., Enable Capital Management, LLC, Enable Growth Partners, LP, Enable Opportunity Partners LP, Fidelity Management & Research Company LLC, Fonds de solidarité FTQ, Fonds régionaux de solidarité FTQ S.E.C. Laval, Frazier Management, L.L.C. (Anna Chen, James Brush, James Topper), Heights Capital Management, Inc., Hudson Bay Capital Management LP, Hudson Bay Fund LP, Hudson Bay Master Fund Ltd, Innovatech Grand Montreal, Iroquois Capital Management, LLC, Iroquois Master Fund Ltd., JGB Capital LP, JGB Management Inc., OrbiMed Advisors LLC, Pharmascience Inc., Picchio Pharma, Inc., Portside Growth and Opportunity Fund, Power Sustainable Capital Inc., Power Technology Investment Corporation, Quorum Group of Companies, Radcliffe Capital Management, L.P., Radcliffe SPC Ltd., RTW Investments, LP, Tang Capital Management, LLC, Tang Capital Partners, LP

Investment Arms
BELLUS Health Inc., Asset Management Arm


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
BELLUS Health (Innodia) Inc.
BELLUS Health (Innodia) Inc., a biotechnology company, develops and markets compunds for the treatment and prevention of obesity, type 2 diabetes, and associated diseases. The company's development products include Adyvia for the treatment of obesity; and Anti-Amyloid for the treatment of diabetes. BELLUS Health (Innodia) Inc. was formerly known as Innodia Inc. As a result of acquisition by BELLUS Health Inc. Innodia Inc.'s name was changed. The company was founded in 2002 and is based in Laval, Canada. As of July 17, 2008, BELLUS Health (Innodia) Inc. operates as a subsidiary of BELLUS Health Inc.

United States and Canada
Biotechnology
-
-
-
Neurochem (International) Limited
Neurochem (International) Limited manufactures and distributes therapeutic drugs. The company was incorporated in 2003 and is based in Lausanne, Switzerland. Neurochem (International) Limited operates as a subsidiary of BELLUS Health Inc.

Europe
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-18-2023
Jun-28-2023
Merger/Acquisition
Target
BELLUS Health Inc.
GSK plc (LSE:GSK)

1,970.57
Nov-14-2022
-
Public Offering
Target
BELLUS Health Inc.


80.00
Aug-26-2022
-
Shelf Registration
Target
BELLUS Health Inc.


500.00
Jul-13-2022
Jul-13-2022
Public Offering
Target
BELLUS Health Inc.


153.00
Apr-19-2022
Jun-28-2023
Shelf Registration
Target
BELLUS Health Inc.


31.84
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-30-2023
Annual General Meeting
BELLUS Health Inc., Annual General Meeting, Jun 30, 2023
Jun-29-2023
Index Constituent Drops
BELLUS Health Inc.(TSX:BLU) dropped from S&P Global BMI Index
Jun-29-2023
Index Constituent Drops
BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Composite Index
Jun-29-2023
Index Constituent Drops
BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Completion Index
Jun-29-2023
Index Constituent Drops
BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Capped Composite Index

Competitors
GE Healthcare Limited

M&A Advisors
Bloom Burton Securities Inc., Centerview Partners LLC, Davies Ward Phillips & Vineberg LLP, Geller Biopharm Inc., Skadden, Arps, Slate, Meagher & Flom LLP, Wilson Sonsini Goodrich & Rosati, P.C.


Advisors
Most Recent Auditor
KPMG Limited
M&A Advisors
Bloom Burton Securities Inc., Centerview Partners LLC, Davies Ward Phillips & Vineberg LLP, Geller Biopharm Inc., Skadden, Arps, Slate, Meagher & Flom LLP, Wilson Sonsini Goodrich & Rosati, P.C.
Private Placement Advisors
Davies Ward Phillips & Vineberg LLP, Direct Markets Holdings Corporation
Public Offering Advisors
Davies Ward Phillips & Vineberg LLP, Goodwin Procter LLP, KPMG LLP, KPMG LLP (Canada), Robert W. Baird & Co. Incorporated, Troutman Pepper Hamilton Sanders LLP
Key development Advisor
Lazard Ltd (NYSE:LAZ)


Most Recent Auditor
KPMG LLP - Klynveld Peat Marwick Goerdeler


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Oct 06, 2023 01:36 AM
BELLUS Health Inc.
BELLUS Health Inc (BLU.TSE) - Financial and Strategic SWOT Analysis Review
Reports
108
GlobalData

Sep 28, 2023 06:18 AM
BELLUS Health Inc.
BELLUS Health Inc (BLU.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
46
GlobalData

Sep 20, 2023 05:07 AM
BELLUS Health Inc.
BELLUS Health Inc (BLU.TSE) - Financial and Strategic SWOT Analysis Review
Reports
109
H.C. Wainwright & Co.
Fein, Andrew S.
Aug 18, 2023 04:01 AM
BELLUS Health Inc.
BLU: Dropping Coverage
Reports
3
BTIG
Zelin, Justin Reid
Jul 06, 2023 03:27 PM
BELLUS Health Inc.
Bellus Health - BLU
Reports
5
CFRA Equity Research

Jun 24, 2023 06:19 PM
BELLUS Health Inc.
BELLUS Health Inc.
Reports
9
Pechala's Reports

Jun 23, 2023 11:00 PM
BELLUS Health Inc.
BELLUS HEALTH INC COMMON (BLU=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS
Reports
2
Ford Equity Research

Jun 22, 2023 10:00 PM
BELLUS Health Inc.
Ford Research Report - BELLUS Health Inc.
Reports
3
GlobalData

Jun 21, 2023 05:41 AM
BELLUS Health Inc.
BELLUS Health Inc (BLU.TSE) - Financial and Strategic SWOT Analysis Review
Reports
164
BTIG
Zelin, Justin Reid
Jun 16, 2023 01:02 PM
BELLUS Health Inc.
Shareholder Vote Approves GSK Acquisition; Quebec Application Next Week; Closing Expected End Of 2Q23E.
Reports
6


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


GAMCO Investors, Inc.

745,947

-

11.0

Jun-30-2023


First Trust Capital Management L.P.

696,723

-

10.2

Jun-30-2023


Syquant Capital SAS

370,131

-

5.4

Jun-30-2023


Carmignac Gestion SA

220,882

-

3.2

Jun-30-2023


Azimut Capital Management Sgr SpA

150,000

-

2.2

Jun-30-2023


Vazirani Asset Management LLC

109,620

-

1.6

Jun-30-2023


Barclays Bank PLC,  Securities Investments

76,447

-

1.1

Jun-30-2023


PenderFund Capital Management Ltd.

56,930

-

0.8

Jun-30-2023


Ersel Asset Management Sgr S.p.A.

48,000

-

0.7

Jun-30-2023


MD Financial Management Inc.

16,685

-

0.2

Jun-30-2023



No Data Available.



Top Buyers
Buyers
Common Stock Equivalent Held
Change
First Trust Capital Management L.P.
696,723
696,723
Syquant Capital SAS
370,131
370,131
Carmignac Gestion SA
220,882
220,882
Azimut Capital Management Sgr SpA
150,000
150,000
Vazirani Asset Management LLC
109,620
109,620

Top Sellers
Sellers
Common Stock Equivalent Held
Change
RA Capital Management, L.P.
0
(12,643,574)
Goldman Sachs Group, Investment Banking and Securities Investments
0
(7,413,933)
Pictet Asset Management Limited
9,477
(7,062,666)
Commodore Capital LP
0
(6,579,359)
OrbiMed Advisors LLC
0
(5,108,900)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
ALZ-801 (Future), ALZHEMED (Future), AMO-01 (Future), Camlipixant (Future), Carboxylates, Cerebril (Future), KIACTA (Future), Licensing of BLU8499, Licensing of KIACTA, Licensing of VIVIMIND, Pharmacophores, Phosphonates, Sulfates, Sulphonates


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Reporting Owner(s)
Source
Form Type
Language
Size
Jun-28-2023
-
BELLUS Health Inc.
The NASDAQ Stock Market LLC
SEC
25-NSE
English
3 KB
Jun-28-2023
Jun-28-2023
BELLUS Health Inc.

SEC
6-K
English
29 KB
Jun-28-2023
-
BELLUS Health Inc.

SEDAR
Change in Corporate Structure
English
103 KB
Jun-28-2023
-
BELLUS Health Inc.

SEDAR
Change in Corporate Structure
English
81 KB
Jun-28-2023
-
BELLUS Health Inc.

SEDAR
Material Change Report
French
138 KB
Jun-28-2023
-
BELLUS Health Inc.

SEDAR
Material Change Report
English
137 KB
Jun-28-2023
-
BELLUS Health Inc.

SEDAR
Securities Acquisition Filings (Early Warning)
English
120 KB
Jun-28-2023
-
BELLUS Health Inc.

SEDAR
Documents Affecting the Rights of Security Holders
English
1 MB
Jun-28-2023
-
BELLUS Health Inc.

SEDAR
News Releases
French
120 KB
Jun-28-2023
-
BELLUS Health Inc.

SEDAR
News Releases
English
105 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Bellini GU, OC, Francesco  (Chairman of the Board)
Jun-21-2023
Common Shares
(104,937)
(2,108,638)
Other Disposition
(19.23)
Multiple
Bellini, Roberto Francesco (President, CEO & Director)
Jun-21-2023
Common Shares
(735,616)
(14,781,705)
Other Disposition
(28.94)
Multiple
Garceau Ph.D., Denis  (Chief Scientific Officer)
Jun-20-2023
Common Shares
317,222
2,488,262
Derivative Exercise and Retained Stock
46,926.33
Multiple
-
Jun-20-2023
Common Shares
97,222
434,220
Derivative Exercise and Retained Stock
-
Exchange Announcement
-
Jun-20-2023
Common Shares
90,000
1,283,591
Derivative Exercise and Retained Stock
-
Exchange Announcement
-
Jun-20-2023
Common Shares
130,000
770,451
Derivative Exercise and Retained Stock
-
Exchange Announcement
Matzouranis, Tony  (Chief Business Officer)
Jun-20-2023
Common Shares
159,845
0
Derivative Exercise and Retained Stock
New
Multiple
-
Jun-20-2023
Common Shares
64,660
0
Derivative Exercise and Retained Stock
-
Exchange Announcement
-
Jun-20-2023
Common Shares
21,334
0
Derivative Exercise and Retained Stock
-
Exchange Announcement
-
Jun-20-2023
Common Shares
73,851
0
Derivative Exercise and Retained Stock
-
Exchange Announcement
Naud, Nathalie 
Jun-20-2023
Common Shares
49,089
395,680
Derivative Exercise and Retained Stock
New
Multiple
-
Jun-20-2023
Common Shares
13,889
62,032
Derivative Exercise and Retained Stock
-
Exchange Announcement
-
Jun-20-2023
Common Shares
15,000
213,932
Derivative Exercise and Retained Stock
-
Exchange Announcement
-
Jun-20-2023
Common Shares
20,200
119,716
Derivative Exercise and Retained Stock
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Bellini, Francesco 
Chairman of the Board
450 680 4500
450 680 4501

Bellini, Roberto Francesco
President, CEO & Director
450 680 4500
450 680 4501

Berger, Franklin M.
Independent Director
450 680 4500
450 680 4501

Larochelle, Pierre 
Independent Lead Director
450 680 4500
450 680 4501

Rus, Joseph 
Independent Director
450 680 4500
450 680 4501

Desjardins, Clarissa 
Independent Director
450 680 4500
450 680 4501

Mezzanotte, William 
Independent Director
450 680 4500
450 680 4501

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bellini, Roberto Francesco
President, CEO & Director
450 680 4500
450 680 4501

Orfanos, Andreas 
Chief Operating Officer
450 680 4500
450 680 4501

Garceau, Denis 
Chief Scientific Officer
450 680 4500
450 680 4501

Matthews, Daniel 
Director of Investor Relations & Communications
917-828-0414
450 680 4501
danny@bellushealth.com
Bonuccelli, Catherine M.
Chief Medical Officer
450 680 4500
450 680 4501

Matzouranis, Tony 
Chief Business Officer
450 680 4500
450 680 4501

Roy, Sebastien 
Corporate Secretary
450 680 4500
450 680 4501
sroy@chateaumsa.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
